Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1995-04-19
1997-04-22
Jordan, Kimberly
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514510, 514824, A61K 3140, A61K 3121
Patent
active
056229852
ABSTRACT:
A method is provided for preventing or reducing the risk of a second heart attack in a patient having a substantially normal serum cholesterol level by administering an HMG CoA reductase inhibitor such as pravastatin, alone or in combination with an ACE inhibitor.
REFERENCES:
patent: 4346227 (1982-08-01), Terahara et al.
patent: 4920123 (1990-04-01), Beyer
patent: 5008284 (1991-04-01), Grover et al.
Cecil, Textbook of Medicine, 16 Ed., pp. 239-242. (1983).
Schettler, G., "The role of diet and drugs in lowering serum cholesterol in the postmyocardial infarction patient," Cardiovasc. Drugs, Ther., 1989, 2/6 (795-799).
Glatter, T.R., "Hyperlipidemia. What is `normal`, who should be treated and how," Postgrad. Med., 1984, 76/6 (49-50).
Satler, L.F., et al, "Reduction in coronary heart disease: Clinical and anatomical considerations," Clin. Cardiol., 1989, 12/8 (422-426).
Wilhelmsen, L., "Practical Guidelines for drug therapy after myocardial infarction," Drugs, 1989, 38/6 (1000-1007).
Yamamoto. A., et al., "Clinical features of familial hypercholeterolemia," Arteriosclerosis, Jan.-Feb. 1989, 9 (1 Suppl.) pp. 166-174.
Goldstein, J.L., et al, "The LDL receptor defect in familial hypercholesterolemia. Implications for pathogenesis and therapy,"0 Med. Clin North Am., 1982, 66/2 (335-362).
Osborne, J.A., et al, "Anti-ischemic Actions of Lovastatin (1) in Hypercholesterolemic Rabbits," Abstract of the 61st Scientific Sessions. (1989).
Tsujita, Y. "A Potent HMG-CoA Reductase Inhibitor, Pravastatin Sodium-Tissue-Selective Inhibition of Cholesterolgenesis and Preventive Effect on Atherosclerosis in WHHL Rabbits," J. Drug Dev. 1900:3(Suppl. 1), 155-159.
Maher, V.M., et al, "Analysis of Evidence from Cholesterol-Lowering and Regression Trials," J. Drug Dev. 1990:3 (Suppl. 1) 199-203.
Lewis, B. "On lowering lipids in the post-infarction patient," Journal of Internal Medicine 1991; 29:483-488.
"A Coronary Primary Prevention Study of Scottish Men Aged 45-64 Years: Trial Design," J. Clin Epidemiol vol. 45, No. 8 pp. 849-860, 1992.
Sacks, F.M., "Desirable Serum Total Cholesterol With Low HDL Cholesterol Levels," Circulation, vol. 86, No. 4, Oct. 1992, pp. 1341-1344.
Sacks, F.M., et al, "Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients", The Lancet, vol. 344, Oct. 1994, pp. 1182-1186.
Goldman, L., et al, "Projected Cost-Effectiveness of Lovastatin for Cholesterol Reduction," Clin. Res. (36, No. 3, 337A, 1988).
Sacks, F.M. et al, "Rationale and Design of a Secondary PreventionTrial of Lowering Normal Plasma cholesterol Levels After Acute Myocardial . . . Recurrent Events Trial (CARE)" , Am. J. Card. vol. 68, Dec. 1, 1991, pp. 1436-1446.
Fuster, V., et al, "Atherosclerotic Plaque Rupture and Thrombosis," Suppl. II, Circulation, vol. 82, No. 3, Sep. 1990, II-47-II59.
Crouse, J.R., et al, "Pravastatin, Lipids and Atherosclerosis in the Carotid Arteries: Design Features of a Clinical Trial with Carotid Atheroscelosis Outcome," Controlled Clinical Trails 13:495-506 (1992).
Edelman, S., et al., "Hyperkalemia During Treatment with HMG-CoA Reductase Inhibitor," New Engl. J. of Med., vol. 320, No. 18, May 4, 1989, pp. 1219-1220.
Pitt, B., et al, "design and Recruitment in the United States of a Multicenter Quantitative Angiographic Trial of Pravastatin to Limit Atherosclerosis in the Coronary Arteries" (PLAC I), Amer. J. Card., vol. 72, Jul. 1, 1993, pp. 31-35.
"Effects of Pravastatin in Patients with Serum Total Cholesterol Levels from 5.2 to 7.8 mmol/liter (200 to 30 mg/dl) Plus Two Additional Atherosclerotic Risk Factors," Am. J. Card., Nov. 1, 1993, pp. 1031-1037.
Pearson, T.A., et al, "The Rapid Reduction in Cardiac Events with Lipid-Lowering Therapy: Mechanisms and Implications," Am. J. Card., vol. 72, Nov. 1, 1993, pp. 1072-1073.
Alexander John C.
Olukotun Adeove Y.
Bristol--Myers Squibb Company
Jordan Kimberly
Rodney Burton
LandOfFree
Method for preventing a second heart attack employing an HMG CoA does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for preventing a second heart attack employing an HMG CoA, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for preventing a second heart attack employing an HMG CoA will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-342124